FUDANZHANGJIANG

Country

Ownership: -

Established: 1996-11-11

Employees: 948

Market Cap: -

Website: http://www.fd-zj.com

Introduction: The company was founded in November 1996 in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, with well-known enterprises such as Shanghai Pharmaceutical Group Co., Ltd. as shareholders of the company. It is mainly engaged in innovative research and development, manufacturing and marketing of biomedicine. Main products: Dermatological products, anti-tumor products, etc. Corporate honors: Jiangsu High-tech Enterprise, 2017 Economic Outstanding Contribution Award, Shanghai Enterprise Technology Center, etc.

Clinical Trials

Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis

Phase 3

Completed

Conditions: PBC

Interventions: Drug: UDCA
Drug: OCA
Drug: Placebo

First Posted Date: 2024-12-04

Last Posted Date: 2024-12-04

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06715319

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: FDA018-ADC
Drug: Eribulin
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06519370

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Phase 2

Completed

Conditions: Cervical Intraepithelial Neoplasia Grade 2
Papillomavirus Infections
p16 Protein

Interventions: Drug: Placebo
Drug: Aminolaevulinic acid (500-mg bottle)
Drug: Aminolaevulinic acid (750-mg bottle)

First Posted Date: 2024-06-03

Last Posted Date: 2024-06-03

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 119

Registration Number: NCT06439433

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

and more 2 locations

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)

Interventions: Drug: FZ-AD005

First Posted Date: 2024-05-22

Last Posted Date: 2024-07-24

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 162

Registration Number: NCT06424665

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）

Phase 3

Recruiting

Conditions: 5-aminolevulinic Acid
Malignant Glioma of Brain

Interventions: Drug: 5 Aminolevulinic Acid

First Posted Date: 2024-05-16

Last Posted Date: 2024-07-31

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT06417281

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China

A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

Phase 2

Not yet recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: FDA022-BB05

First Posted Date: 2024-05-14

Last Posted Date: 2024-05-14

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT06413615

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced and Metastatic Solid Tumor

Interventions: Drug: FZ-AD004

First Posted Date: 2023-06-22

Last Posted Date: 2024-05-17

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 121

Registration Number: NCT05914545

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia

First Posted Date: 2022-10-04

Last Posted Date: 2024-05-17

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 107

Registration Number: NCT05564858

Locations: 🇨🇳
Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Beijing, Beijing, China

A Study of FDA018-ADC in Patients with Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced/ Metastatic Solid Tumors

Interventions: Drug: FDA018-ADC

First Posted Date: 2022-01-03

Last Posted Date: 2025-03-10

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 78

Registration Number: NCT05174637

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin + PDT

Phase 2

Recruiting

Conditions: Port-wine Birthmarks
Port-Wine Stain
Nevus Flammeus

Interventions: Drug: Hemopfin+Green Light
Device: Vehicle+Green Light

First Posted Date: 2021-12-29

Last Posted Date: 2024-08-01

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 84

Registration Number: NCT05171894

Locations: 🇺🇸
UCI Health Beckman Laser Institute & Medical Clinic, Irvine, California, United States
🇺🇸
Dermatology Cosmetic Associates of La Jolla, Inc. d/b/a West Dermatology Research Center, San Diego, California, United States
🇺🇸
Skin and Cancer Associates (SCA) and the Center for Cosmetic Enhancement (CCE), Aventura, Florida, United States

and more 3 locations

Home Terms & Conditions Privacy Policy